Articles tagged with Vaccine Research
A new framework integrates all stages of carbohydrate vaccine development, from antigen production to clinical evaluation. The framework highlights emerging technologies like automated glycan assembly and AI-driven glycoscience to transform vaccine design.
Researchers found that mRNA-based COVID-19 vaccines effectively protected Schistosoma-infected mice against SARS-CoV-2, with strong spike-specific antibody responses and CD4 T-cell immunity. The findings suggest that chronic helminth infection does not necessarily compromise vaccine-induced protection.
A new study reveals that Republican lawmakers sponsored 86% of antivaccine bills introduced in state legislatures after the COVID-19 pandemic. Meanwhile, Democratic lawmakers supported provaccine bills, highlighting partisan polarization's impact on vaccine access and public health.
A vaccine targeting KRAS mutations was safe and stimulated durable immune responses in high-risk individuals. After a median follow-up of 16.5 months, none of the participants developed pancreatic cancer, and some precancerous lesions shrank or stopped growing.
A study found that measles-containing vaccines were administered to only 15% of children in this age group between 2015 and 2025. This proportion remained stable over time, but disparities in vaccine uptake existed among minoritized racial and ethnic groups.
Genital herpes is a viral infection that establishes a lifelong infection by entering nerve cells and can be relieved with medication. Researchers have identified glycoprotein G as a promising target for a future vaccine, which could provide protection against HSV-2 spread to the nervous system.
A new study at RMIT University has identified conditions that help protect mRNA particles in dry vaccine patches, providing practical guidance for future patch design. This research could make future mRNA vaccines easier to store and distribute, particularly in lower-resource settings where cold-chain logistics are a barrier.
Scientists at La Jolla Institute for Immunology and Scripps Research have developed an HIV vaccine that trains immune cells to see past HIV's defenses. The vaccine resulted in the best HIV-fighting antibody response ever seen in primates, with human trials now underway.
A new study found that BCG vaccines can modify Alzheimer's biomarkers in non-Alzheimer's participants, suggesting a potential biological explanation for the observed link between BCG vaccination and lower disease risk. The vaccine also promoted increased immune responses in healthy participants without Alzheimer's pathology.
A new vaccine, SchistoShield, has triggered an immune response and trained the body to remember it, according to researchers. The vaccine has shown effectiveness in both US and African populations, with robust cell-mediated effector and memory responses observed.
Researchers found that a daily spermidine supplement improved immune response to COVID-19 vaccination in older adults. Spermidine reduced markers of immunosenescence and stimulated autophagy, leading to higher antibody levels and better neutralizing activity against multiple viral variants.
In a phase 1 clinical trial, researchers found the LASSARAB vaccine to be safe and well-tolerated, inducing strong immune responses against Lassa fever and rabies. The vaccine demonstrated robust neutralizing antibody levels against the rabies virus, exceeding WHO's established threshold for protection.
A new study found that AI-powered chatbots can make vaccine-hesitant parents more likely to say they will immunize their children against HPV, but no more than standard written public health materials. Additionally, the effects of the chatbots did not last longer than those of government health materials.
A universal Sarbeco coronavirus vaccine has shown safety and no significant side effects in a human clinical trial, providing protection against multiple viruses, including SARS-CoV-2. The vaccine uses an AI-designed super-antigen to offer lasting protection against emerging virus threats.
The new vaccine adjuvant induces a strong mucosal immune response in the GI tract, which is crucial for eradicating polio. The researchers achieved a 20-fold increase in antibodies needed for mucosal immunity compared to the existing injectable polio vaccine.
A study of over 1,000 people vaccinated with TAK-003 in Catalonia found no serious adverse events and provided new evidence on the vaccine's short-term safety in travelers. The findings suggest that the dengue vaccine has a good tolerability profile among travelers from non-endemic regions.
A new study shows that a cancer vaccine in combination with immunotherapy reduces the risk of skin cancer recurrence and death by 49 percent. After five years, patients who received the combination therapy had a 68.8% chance of remaining cancer-free compared to 50.2% for those receiving immunotherapy alone.
Researchers at La Jolla Institute for Immunology have discovered that combining key vaccine ingredients could give the body the tools it needs to fight the entire family of arenaviruses with a single vaccine. This approach may protect against life-threatening infections from Lassa virus, Junin virus, and many other arenaviruses.
A new mRNA-based strategy amplifies the T-cell response to vaccines, enabling more powerful cancer vaccines and stronger protection against infectious diseases. The approach reprograms immune cells from within using mRNA instructions that expand cancer-fighting T cells.
A systematic review of 59 studies found no association between aluminium-adjuvanted vaccines and serious or long-term health outcomes, including autism, type 1 diabetes, asthma, and myalgia. Persistent nodules or granulomas at the injection site were the most consistently documented reactions.
A growing gap in cervical cancer incidence rates between high- and low-income countries threatens to escalate unless prevention efforts are increased. Researchers urge universal vaccination for girls and boys, as well as catch-up campaigns, to close the gap and prevent nearly 37 million cases of cancer by the end of the century.
Researchers at La Jolla Institute for Immunology discovered that FluMist can trigger an immune response directly in nasal tissue, training immune cells to recognize and fight influenza virus infection. This response stays in the upper airways and cannot be detected via blood samples.
A new Johns Hopkins University study reveals a significant link between following 'new right' media outlets and vaccine hesitancy. The research surveyed nearly 3,000 adults, finding that those who engage with these outlets are more than twice as likely to be hesitant about vaccines.
A nationally representative survey found that nearly 7 in 10 people trust vaccine scientists to act in their best interests, similar to medical scientists and scientists in general. The public perceives vaccine scientists as credible, self-correcting, and unbiased, with their work benefiting society.
A new study found that infants receiving maternal RSV vaccination or Nirsevimab after birth had significantly lower RSV infection rates and fewer severe complications. The study showed a high uptake of the vaccines among pregnant patients and newborns, leading to declining rates of RSV-related illnesses.
Researchers at the University of Nebraska-Lincoln have developed a promising new vaccine approach against highly pathogenic bird flu (H5N1) that demonstrates strong efficacy in both mice and dairy cattle. The vaccine platform protects against multiple H5N1 strains and generates immunity in both the bloodstream and respiratory tract.
Recent studies have explored tumor vaccine platforms, including peptide, dendritic cell, and nucleic acid-based vaccines. Personalized neoantigen vaccines are refining precision in HCC treatment, but challenges persist due to immunosuppressive tumor microenvironments and heterogeneity.
Researchers developed a new flu vaccine approach targeting specific but distinct regions of the influenza virus protein. This method broadened the immune response, leading to broader protection against various strains. The study's findings have implications for fighting other fast-changing viruses like COVID-19 and RSV.
Researchers have found that COVID vaccines can train immune cells to remember the SARS-CoV-2 virus and protect against severe infection for years afterward. However, the continued spread of disease has scientists taking a closer look at how the immune system builds up immune memory over time.
Researchers found that squalene-based adjuvants activate distinct pathways for vaccine protection and reactogenicity, including the role of IL-1β in enhancing efficacy and IL-1α in triggering local swelling. The study's findings could lead to safer vaccine design by targeting specific immune mechanisms.
Researchers found that obesity significantly impaired antibody production to a Pseudomonas aeruginosa vaccine in mouse models. The study suggests prioritizing tissue-resident immunity to boost protection against infections. Understanding this relationship addresses a significant gap in current vaccine research.
A randomized, open-label bridging clinical trial was conducted to evaluate the immunogenicity and safety of a 9-valent HPV vaccine in adolescents aged 9-17 years compared to young women. The study found non-inferior immune responses with seroconversion rates comparable to those in young women receiving three doses.
Two new TB vaccines, VPM1002 and Immuvac, demonstrate safety and effectiveness in preventing progression to active TB in latent infection, particularly in children. However, they do not offer general protection against all forms of TB or prevent weight-related mortality.
Persistent inequalities remain a major barrier to achieving universal protection against life-threatening infections. The study found that PCV booster retention has dropped in England since the schedule change, disproportionately affecting children in more deprived areas.
Researchers at UW–Madison identified a way to program longer-lasting T cells, which can recognize more stable parts of viruses and offer a path to broader protection. The new strategy has the potential to provide longer-lasting immunity against respiratory infections like the flu and COVID-19.
Researchers have developed experimental compounds that block flu viruses by locking onto their surface enzyme, potentially improving treatments and pandemic preparedness. The new approach shows promise in stopping common types of flu virus, including H3N2 and bird flu strains.
The Linda and Mike Mussallem Foundation has donated to USC's Keck School of Medicine to enhance clinical trials for individuals with Down syndrome at risk for Alzheimer's. This will increase domestic and international sites, accelerating the development of treatments specifically for this population.
Researchers redesigned a key component of lipid nanoparticles to steer particles toward lymph nodes, reducing off-target delivery. This advancement could make mRNA vaccines more efficient, potentially achieving strong immune protection at lower doses.
Researchers discovered a new layer of defense in the lungs, where specialized immune cells coordinate a local response to viral infections. The study found that these cells produce a protein called HIF-1α, which activates neighboring immune cells to mount a coordinated defense.
Researchers at the University of Pennsylvania developed lipid nanoparticles that modify immune metabolism to strengthen mRNA vaccines and reduce common side effects. The new lipid boosts the metabolism of immune cells, providing energy for the body's defenses while dialing down inflammatory signals.
A recent study found that people with atherosclerotic heart disease who received the shingles vaccine had nearly half the rate of serious cardiac events compared to those who did not get vaccinated. The vaccine was associated with significant reductions in cardiovascular risk, including heart attacks, strokes, and death.
A Simon Fraser University study found cultural, administrative, and governance barriers reinforce mistrust and limit vaccine access. Community-led clinics and trusted messengers can increase access and trust, but remain underfunded and excluded from decision-making.
A new study discovered that a multifaceted infection prevention and control intervention successfully disrupted a large and long-running bacterial outbreak of Klebsiella pneumoniae in a Zambian neonatal intensive care unit. The study found that low-cost measures, including IPC training, enhanced cleaning, and hand hygiene, reduced neon...
A Purdue University-developed contraceptive vaccine reduces fertility in feral horses, deer, swine, and other animals, overcoming limitations of existing models. The vaccine, based on a male sperm protein, induces a long-lasting immune response and infertility in female mammals, with promising results for wildlife management.
A randomized, double-blind clinical trial found that a natural fungal supplement, FoTv, reduced short-term vaccine side effects and helped antibodies last longer in people who had not previously been exposed to COVID-19. The study suggests that FoTv may help strengthen vaccine protection without increasing side effects.
The American College of Physicians advises all adults aged 75 or older to receive a protein subunit Respiratory Syncytial Virus (RSV) vaccine, reducing the risk of severe illness and hospitalization. Adults aged 60-74 with comorbid conditions may also consider receiving the vaccine. The benefits outweigh the harms in this age group.
Researchers at the University of Texas at Austin have created a high-resolution 3D map of the Andes virus, a crucial step towards developing vaccines and treatments against hantaviruses. The new structure allows for the design of effective vaccines and antibody therapies.
A novel vaccination approach cleared harmful gut bacterium Clostridioides difficile (C. diff) in an animal model of infection. The experimental vaccine protected against illness, death, tissue damage and infection recurrence through mucosal immunization.
A new study has shown that hospital analysers can accurately distinguish genuine liquid medical products from fakes, providing a low-cost screening tool to complement established methods. This breakthrough addresses a global health threat, with an estimated 10.5% of medicines worldwide being substandard or fake.
Researchers at Ragon Institute discovered that antibodies produced in germinal centers act as a 'brake' on selection, redirecting the immune system toward broader protection. Stronger-binding B cells suppress weaker ones targeting the same site, establishing a localized feedback loop.
A newly described HIV antibody targets the V3 glycan site in a different manner than previously known antibodies, remaining effective against virus variants that are resistant to classical V3 antibodies. This breakthrough supports antibody therapy combinations that neutralize the virus more effectively.
The VALIDATE Network has achieved significant milestones in global collaboration for vaccine research, with over £3.5M in grants and £25.5M in follow-on funding secured. The network has supported over 86 novel publications and delivered online seminars and workshops to more than 3,400 attendees.
Researchers have identified a molecular trigger for rare blood clotting conditions after COVID19 adenovirus-based vaccines or natural adenovirus infections. The exact cause is now understood, allowing vaccine developers to adjust the adenovirus protein and prevent this extremely rare reaction.